FDA flags chlorthalidone blood pressure pills in second Inventia recall
Inventia Healthcare Limited is recalling 13,567 bottles of Chlorthalidone Tablets, USP, 25 mg after the pills failed dissolution testing, a quality check that measures how the drug breaks down in the body.
The recalled bottles are part of a blood pressure medication sold in 100-tablet and 1,000-tablet sizes, with an expiration date of April 2027. The FDA has identified the recall as Class II, which means the product may cause temporary or medically reversible adverse health consequences, while serious harm is considered remote.
Chlorthalidone is a diuretic, or water pill, used to lower blood pressure by helping the kidneys remove salt and water. If a tablet does not dissolve properly, the active ingredient may not be absorbed as intended.
This is the second chlorthalidone recall from Inventia Healthcare this year. The company previously recalled 11,460 bottles on June 5.
The breakdown in dissolution testing raises concerns about reduced effectiveness over time, especially for people taking the medicine to manage blood pressure.